Displaying drugs 7401 - 7425 of 8033 in total
Zuretinol acetate
Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).
Investigational
Matched Description: … Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis …
Inclacumab
Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
Investigational
Matched Description: … Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral …
AFN-1252
AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection, Cutaneous Abscess, and Skin and Subcutaneous Tissue Bacterial Infections.
Investigational
Matched Description: … AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection …
CP-547632
CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
Investigational
Matched Description: … CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms …
Foxy-5
Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.
Investigational
Matched Description: … Foxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic …
Hycanthone
Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Experimental
Matched Description: … Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. …
Olendalizumab
Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
Investigational
Matched Description: … trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of …
Fosifloxuridine nafalbenamide
Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).
Investigational
Matched Description: … Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of …
Uteroglobin
Uteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).
Investigational
Matched Description: … Uteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of …
Cobomarsen
Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).
Investigational
Matched Description: … Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of …
Seltorexant
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
Investigational
Matched Description: … Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of …
Cystic fibrosis transmembrane conductance regulator
Cystic fibrosis transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis).
Investigational
Matched Description: … transmembrane conductance regulator is under investigation in clinical trial NCT00004806 (Phase I Study of …
PD-0299685
PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).
Investigational
Matched Description: … is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of …
CB-103
CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).
Investigational
Matched Description: … CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced …
Hydroxypropyl betadex
Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C).
Investigational
Matched Description: … Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile …
LB-100
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
Anivamersen
Anivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).
Investigational
Matched Description: … is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of …
Carotegrast methyl
Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).
Investigational
Matched Description: … methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of …
CXD101
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
Milvexian
Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).
Investigational
Matched Description: … Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of …
Selodenoson
Selodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1-adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation).
Investigational
Matched Description: … Selodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1- …
Ohmefentanyl
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which...
Illicit
Matched Description: … Researchers are studying the different pharmaceutical properties of these isomers. ... Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids …
LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications...
Investigational
Matched Description: … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered ... For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of …
Topsalysin
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
Investigational
Matched Description: … Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic …
Manitimus
FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Investigational
Matched Description: … FK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in …
Displaying drugs 7401 - 7425 of 8033 in total